Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

Adding aflibercept to gemcitabine did not improve OS in patients with metastatic pancreatic cancer.